Jpmorgan Chase & CO Cytosorbents Corp Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Cytosorbents Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 494 shares of CTSO stock, worth $538. This represents 0.0% of its overall portfolio holdings.
Number of Shares
494
Previous 372
32.8%
Holding current value
$538
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CTSO
# of Institutions
58Shares Held
15.7MCall Options Held
16KPut Options Held
0-
Avenir Corp Washington, DC3.09MShares$3.37 Million0.29% of portfolio
-
Skylands Capital, LLC2.78MShares$3.03 Million0.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$2.13 Million0.0% of portfolio
-
Neuberger Berman Group LLC New York, NY1.68MShares$1.83 Million0.0% of portfolio
-
Sargent Investment Group, LLC1.25MShares$1.36 Million0.18% of portfolio
About Cytosorbents Corp
- Ticker CTSO
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 43,577,400
- Market Cap $47.5M
- Description
- Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...